09:27 EDT Valneva (VALN) drops 2% to $6.05 after UK restricts vaccine use
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children
- Valneva says IXCHIQ ‘well tolerated’ by children ages 1-11 years
- Valneva Prepares for Shareholder Meeting and Announces Leadership Change
- Valneva to Engage with Investors at June Conferences
- Valneva’s Chikungunya Vaccine Use Paused for Elderly Amid Safety Review